CMR International

Centre for Medicines Research (CMR) International

The Centre for Medicines Research (CMR) International is the most established and reputable source of pharmaceutical industry metrics and trends analysis. Our experience, independence and integrity coupled with our dedication to providing the best possible data, insights and opinions, makes us the partner of choice for the world’s major pharmaceutical innovators. CMR International is distinguished by its ability to collect, validate and analyze industry-wide proprietary R&D performance metrics, using a proven and secure process. This capability enables us to provide partners with readily accessible information designed to maximize the effectiveness and efficiency of their R&D operations. As a result, CMR International is the world’s most authoritative source of R&D performance metrics, facts and trends.

 

The CMR International performance metrics programs cover every aspect of pharmaceutical R&D. Our programs are ongoing and focused on key issues, with datasets built over 20 years of rigorous development. The datasets have unique depth and historical context to uncover reliable industry trends, set in context against the changing marketplace.

 

Origin and history

CMR International was created in 1981 as a division of the Association of the British Pharmaceutical Industry (ABPI). CMR International’s initial role was to challenge public policy and regulatory issues that could adversely affect drug development. Early success, for example in amending long-term study requirements, placed CMR International at the center of pharmaceutical analysis and reform.

 

In the 1990s, in partnership with the world’s leading pharmaceutical R&D organizations, CMR International pioneered the development of reliable approaches to benchmarking pharmaceutical R&D.

 

In 2002, CMR International became a fully-independent, private company that was acquired by Thomson Reuters IP & Science division in 2006. The IP & Science Division of Thomson Reuters was divested in 2016 under private equity ownership and rebranded as Clarivate Analytics, a standalone entity.  CMR International is a wholly owned subsidiary of Clarivate Analytics. Since 2016, CMR International has been headed by Jamie Munro, Global Practice Leader, Portfolio and Licensing.

 

We continue to collaborate with the independent, not-for-profit organization Centre for Innovation in Regulatory Science (CIRS).  CIRS is the vehicle through which pharmaceutical companies, regulatory authorities, HTAs (Health Technology Assessments) and academia meet, debate and develop regulatory policy.

 

Mission and values

CMR International’s reputation depends entirely on the value and integrity of the information we provide to our long-standing clients. Pharmaceutical companies work with us because produce industry leading metrics that are dependable and our analyses are of the highest quality and integrity.

 

Our reputation is built on rigorous definitions of benchmarking terms that we have developed and refined in close cooperation with our clients. Our meticulous audit procedures guarantee the integrity of the information we provide to our clients.

 

At CMR International, we pride ourselves on being professional, approachable and responsive. We also pride ourselves on the absolute confidentiality in which we hold the information our clients share with us.

 

Work with us

It’s likely you already work with our information, sometimes without knowing it. Our findings and analysis are one of the major sources of pharmaceutical industry information quoted in public and academic communications, and by consultants, specialist commentators and the press.

Terms and Conditions

Products & Services

  • You can work with us by participating in one of our flagship benchmarking programs: Global R&D Performance Metrics Program, Global Clinical Performance Program and Asia Pacific Performance Program
  • Commissioning custom analyses with us that provide you with targeted answers to your questions
  • The CMR International Pharmaceutical R&D Factbook

CMR International Benchmarking programs

In an industry where success depends ever more on objective, actionable data, CMR International programs are the most reliable source that a majority of the world’s leading companies rely on for performance benchmarks supporting a range of activities including strategy, target setting as well as project and clinical trial management.

 

 

Global R&D Performance Metrics Program

The Global R&D Performance Metrics Program provides participating companies with independent, reliable and contemporary R&D benchmarks that senior managers can use with confidence, ease and authority.

Scope of the R&D program

The program is designed to answer the following key questions:

  • What are the most effective and useful metrics for measuring and comparing R&D productivity across the global pharmaceutical industry?
  • What are the latest trends in R&D productivity across the industry?
  • What are the key factors that influence R&D productivity?
  • How do different companies compare — with the industry, with competitors?
  • What are the latest trends in industry pipeline volumes, cycle times and success rates – by therapeutic area and granular indications?
  • Are the timelines and success rates by therapy area being experienced by my company competitive with the rest of the industry and what are the drivers for above or below average performance?

Each participating company will receive a suite of company-specific outputs including benchmarking reports and access to online analytical tools. In addition CMR International organizes several industry round table meetings which provide colleagues  a benchmarking forum to discuss R&D trends with their peers in a confidential and open manner.

 

Global Clinical Performance Metrics Program

The Global Clinical Performance Metrics Program provides participating companies with independent, reliable and up-to-date clinical benchmarks that track the trends in clinical activity.

Scope of the clinical program

The program is designed to answer the following key questions:

  • In which areas of clinical development should my company focus to improve clinical productivity?
  • What are the most important characteristics that influence study cycle times? What is the impact of therapeutic area, active substance type, target novelty, number of sites per study, etc.?
  • How well are countries performing in actually enrolling patients when compared with the numbers that were planned to be enrolled, and converting enrolled patients to treated patients?
  • Within each country what is the variability by site in the number of patients planned versus the number of patients enrolled, the number of patients enrolled versus the number of patients treated, and the enrolment duration?
  • Are my company’s timelines by therapeutic area competitive with the rest of the industry?
  • How does my company’s performance in patient enrollment compare to others in the same therapeutic area and granular indications?
  • Are there any consistently good performers in all aspects of clinical development? If so, what distinguishes the best performers?

Each participating company will receive a suite of company-specific outputs including benchmarking reports and access to analytical online tools. In addition, CMR International organizes several industry round table meetings which provide colleagues a benchmarking forum to discuss R&D development trends with their peers in a confidential and open manner.

 

Asia Pacific Performance Metrics Program

The Pacific Performance Metrics Program provides participating companies with independent, reliable and up-to-date R&D and clinical benchmarks that track the trends in clinical activity in five key countries of Japan, China, India, South Korea and Taiwan. These benchmarks include pipeline progression in the region, success rates, trial density, patient numbers, cycle times and regulatory strategy adopted within the region.

Each participating company will receive a suite of company-specific outputs including benchmarking reports and access to analytical online tools. In addition, CMR International organizes an industry round table meeting which provides colleagues a benchmarking forum to discuss R&D development trends with their peers in a confidential and open manner.

Customized Benchmarking Services

If you do not participate in the flagship benchmarking programs CMR International can partner with you to get the vital, actionable analytical data via a customised approach.

Whether utilizing our expertise in survey development, data manipulation and modelling to address new challenges, or tapping into our extensive datasets to provide a bespoke analysis for your organization, our custom reports are tailored to your particular requirements.

You can use the metrics as a reliable map for establishing your own key milestones and for rapidly identifying deviations from project targets.

You’ll get accurate trend and baseline information against which to measure the impact of future changes and to set realistic targets for future performance. The information you receive can underpin your rationale for investing in new projects, plan resources and manpower, and steer future investment.

The CMR International Pharmaceutical R&D Factbook

The CMR International Pharmaceutical R&D Factbook is the definitive up-to-date business planning report  for decision makers in R&D, corporate finance, business strategy, marketing, clinical operations and corporate communications.

Among many other benefits, The CMR International Pharmaceutical R&D Factbook can help you to:

  • Gain an in-depth understanding of industry dynamics and trends
  • Determine how your organization performs against the market as a whole
  • Gauge your productivity relative to your competitors
  • Recognize the key differences between individual therapeutic areas
  • Appreciate the consequences of adopting different R&D strategies
  • Set internal performance targets that will motivate and challenge your businesses

Fully interactive charts and data

  • Available as a “rich-data” Microsoft PowerPoint file, the slides present our results in a clear, easily-understood format, perfect for presentation.  Each one is accompanied by a succinct explanation of the methodology used and the definitions applied.
  • Includes over 70 robust charts, tables and graphs, which are exportable to other applications.  Simply copy/paste the graphics or slides into your own presentation.
  • Each interactive chart or graph enables you to drill down to the underlying data at the click of a mouse, and analyze the figures behind the trend.

Unlimited user access

  • The rich-data enterprise PowerPoint is accessible to unlimited users within your organization.
  • The file may be installed on a company network/intranet or distributed openly to any employee within your organization.

How to order

Download the rich-data enterprise version with unlimited user access

Speak to our team

Want to learn more about CMR International?

Contact Us